¡Bienvenido a nuestro nuevo sitio web de Sebia!
Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices
Comunicado de Prensa
Abr. 11, 2024
The next generation instrument for screening hemoglobin disorders in newborns.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Comunicado de Prensa
Mar. 07, 2024
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Sebia launches M-inSight®, a test for monitoring multiple myeloma patients
Comunicado de Prensa
Dic. 04, 2023
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
Sebia acquires Zeus Scientific
Comunicado de Prensa
Oct. 12, 2022
The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity
Sebia and Metafora biosystems form strategic partnership to develop advanced in vitro diagnostics
Comunicado de Prensa
Sep. 16, 2021